|Articles|March 15, 2020
- BioPharm International-03-15-2020
- Volume 2020 eBook
- Issue 2
Monograph Development: Why and When to Participate (eBook)
Author(s)J. Mark Wiggins, Joseph A. Albanese
Monographs are developed based on the submission of information and materials from a company having regulatory approval for the product, and this submission feeds into the pharmacopoeia revision process.
Advertisement
Pharmacopoeia Compliance Series
This article explores another proactive advocacy approach that a bio/pharmaceutical company may take through participation in the development of new and revised monographs in the various pharmacopoeias.
This article is part of a series that will be published in 2019–2020.
Article Details
BioPharm International
eBook: Regulatory Sourcebook, March 2020
March 2020
Pages: 12–24
Citation
When referring to this article, please cite it as J.M. Wiggins and J.A. Albanese, “Monograph Development: Why and When to Participate," BioPharm International Regulatory Sourcebook eBook (March 2020).
Articles in this issue
over 5 years ago
Resources, Guidelines, and Guidance Documentsover 5 years ago
Regulatory and Standard Setting Organizationsover 5 years ago
Is There a “New Normal” for Drug Quality?over 5 years ago
A Practical Approach to Pharmacopoeia Compliance (eBook)over 5 years ago
Inside FDA’s New Gene and Cell Therapy GuidancesNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
